The Central Asian Drug Action Programme (CADAP), is currently in its sixth phase and reflects the EU’s long-term engagement with Central Asian partners to help further strengthen their national policies in drug demand reduction.
In a new report published today, Environmental substance use prevention interventions in Europe, the EMCDDA offers a first operational definition of the concept and an initial overview of where and how such interventions are being used in the region.
Environmental prevention policies and interventions seek to limit opportunities for unhealthy or risky behaviour or promote the availability of healthier options in order to prevent problems associated with substance use. They do so by altering the environment in ways that can unconsciously influence behaviour, thus complementing more established approaches that seek to build knowledge and skills.
Today, EMCDDA Director Alexis Goosdeel is in Brussels for an exchange of views with the European Parliament’s Committee for Environment, Public Health and Food Safety (ENVI).
On 22 January 2018, Vermont became the ninth US state to legalise possession of cannabis for recreational purposes, when Governor Phil Scott (Republican) signed House Bill 511 (Text of Act as passed by House and Senate). The law will take effect on 1 July 2018.
This month, the EMCDDA has embarked on work under its Programming Document 2018–20, adopted by the Management Board on 14 December 2017. At its heart is the agency’s vision ‘to contribute to a healthier and more secure Europe’.
As of mid-January, more than 50 000 people had already participated in the European Web Survey on Drugs, a pilot project designed to improve understanding of patterns of drug use at European level.
Director of the European Institute for Gender Equality (EIGE) Virginija Langbakk and EMCDDA Director Alexis Goosdeel are at the European Parliament today where they will present to the Committee on Civil Liberties, Justice and Home Affairs (LIBE).
This month, the EMCDDA has assumed the chairmanship of the EU Agencies’ Network on Scientific Advice (EU-ANSA), one of the sub-networks operating under the tutelage of the Heads of EU agencies network. Its specific purpose is to allow dialogue between senior scientific staff from agencies with a strong science component to their work and to provide scientific and technical advice to EU institutions, Member States and other relevant EU policymakers.
EMCDDA Director Alexis Goosdeel is paying an official visit to the European Centre for Disease Prevention and Control (ECDC) in Stockholm today where he will spend two days discussing opportunities for further collaboration between the two agencies with ECDC Director Andrea Ammon.
In 2013, findings of a first study on drug squads were published in the EMCDDA Paper series. A follow-up study was carried out in 2015 and resulted in the production of this paper. The focus of this limited update is monitoring and analysing changes in the number of specialised drug squads and their staffing levels between 2012 and 2015.
This poster was presented during the WHO Conference on Prison Health, 11-12 December 2017, Lisbon, Portugal. It presents current available data on prevalence of drug use and expert ratings on the availability and level of provision of selected drug interventions for drug users in prison, collected by the EMCDDA national focal points in EU Member States, Turkey and Norway, and supplemented with information from literature reviews.
The University Institute of Lisbon (ISCTE-IUL) and the EU drugs agency (EMCDDA) will be joining forces once again next summer to hold the seventh European drugs summer school (EDSS) on ‘Illicit drugs in Europe: demand, supply and public policies’.
This paper presents the EMCDDA’s current thinking on the conceptual framework for monitoring drug markets, crime and supply reduction — building on the work completed in this area and expanding to reflect the academic research underpinning this work and the developments observed.
This publication presents the data and findings of the risk assessment on N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide (furanylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 23 May 2017. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 15 November 2017, the Council decided that furanylfentanyl should be subject to control measures across the Member States.
This publication presents the data and findings of the risk assessment on N-(1‑phenethylpiperidin-4-yl)-N-phenylacrylamide (acryloylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 22 February 2017. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 25 September 2017, the Council decided that acryloylfentanyl should be subject to control measures across the Member States.
Representatives of candidate, potential candidate and neighbouring countries of the European Union and of Central Asia are joining members of the EMCDDA’s Reitox network in Lisbon today for the kick-off of the agency’s sixth Reitox week.
In a new report out today, the EMCDDA and Europol present the latest understanding of how darknet markets function, the threats they pose and how Europe can respond.
In this issue: Health and social responses to drug problems: a European guide | Lisbon Addictions 2017 | Third international symposium on drug-impaired driving | Testing the waters | Drugs and the darknet | JHA agency directors meet in Lisbon | A faster response to NPS | New EMCDDA products and services | A last word from the editor
This joint report prepared by the EMCDDA and Europol considers the latest findings from international research, fresh empirical data, and operational information and intelligence in order to illuminate how darknet markets function and how they relate to criminal behaviour. The publication adopts an EU focus of what is a global phenomenon.
ECDC and the EMCDDA have systematically retrieved and assessed evidence on active case findings for blood-borne viruses in prison settings in the EU/EEA.
Dimitris Avramopoulos, European Commissioner for Migration, Home Affairs and Citizenship will be at the EMCDDA on 28 November to meet the directors of the nine EU agencies working in the area of Justice and Home Affairs.
A higher prevalence of communicable diseases among people in prison compared with the general public is recognised as a public health issue as well as a major concern for the people affected, as the majority of incarcerated people return to their communities. Active case finding is a key prevention measure to promote early diagnosis, treatment and to prevent further disease transmission. The objective of this report is to systematically review the evidence on active case finding in prison settings, with a focus on the European Union (EU) and the European Economic Area (EEA) region.
Although rare, drug testing in schools continues to be practised in some European countries, where it is seen as a deterrent to use. This paper evaluates the effectiveness of random testing in schools, based on studies conducted among students aged 13 to 19 years, in the United States. Although different with regard to study design and the type of testing offered, all of the studies show that testing has little or no effect on drug use.
Europe’s ability to rapidly respond to public health and security threats caused by new psychoactive substances will be significantly strengthened, thanks to new legislation published today by the European Union.
Today the European Union has decided to subject the new synthetic opioid furanylfentanyl to control measures throughout the EU.
In May 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil), through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 27 July 2017.
This report provides an update on infectious diseases related to injecting drug use in Europe. It covers both the EMCDDA Drug-related infectious diseases indicator, which collects data on the situation, and the responses in the area. The report is based on the indicator’s annual expert meeting, held in Lisbon in June 2017, which brought together national experts from the 28 EU Member States, Norway, Turkey, European neighbourhood countries and partner organisations.